pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca is a pharma organization headquartered in cambridge, GB. Primary therapeutic focus areas include Chronic Obstructive Pulmonary Disease (COPD), Non-Small Cell Lung Cancer, Asthma, Advanced Solid Tumors, Not ap
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
D910GC00001
Phase 3 · small molecule · Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
D910GC00001 for Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition). is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).
Internal code D910GC00001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- AstraZeneca AB
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition).
- Status
- active
- Trials
- 1